Despite billions poured into research, new medicines still typically take a decade or more to develop.

Income investors are drawn to Aristocrats because these stocks have consistently increased their dividends for decades.

A key provision of the Inflation Reduction Act (IRA) of 2022 directed Medicare to negotiate the prices of certain top-selling ...

A new study shows that the US is still behind in controlling the price of prescription drugs. One doctor explains why America ...

The moves will affect more than 300 employees across both companies as both firms look to drive growth in the long term.

Bristol-Myers Squibb can probably continue to grow for a long time. Its dividend looks to be sustainable at the moment. But ...

BeiGene's TEVIMBRA was just approved by the European Commission. Find out what makes BGNE a compelling aggressive growth ...

Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach.

Finding attractive dividend stocks you can hold isn't too difficult. Finding dividend stocks you can comfortably buy and hold ...

We are grateful to our colleagues for their interest and thoughtful comments on our Seminar about systemic lupus erythematosus (SLE).1 We appreciate the remarks from Qihe Xu, and Thomas Pabst and ...

Sudden cardiac arrest and death occur among competitive and recreational athletes across the entire spectrum of age, sex, and ...

Wolfe Research has recently initiated Bristol-Myers Squibb Co (BMY) stock to Peer Perform rating, as announced on November 15, 2024, according to Finviz. Earlier, on November 13, 2024, Daiwa ...